DE3883899T3
(de)
|
1987-03-18 |
1999-04-22 |
Sb2 Inc |
Geänderte antikörper.
|
JP2657221B2
(ja)
|
1988-05-27 |
1997-09-24 |
アプライド・リサーチ・システムズ・エイアールエス・ホールディング・ナムローゼ・フェンノートシャップ |
ヒトFcγレセプター▲III▼
|
ATE356869T1
(de)
|
1990-01-12 |
2007-04-15 |
Amgen Fremont Inc |
Bildung von xenogenen antikörpern
|
US5814318A
(en)
|
1990-08-29 |
1998-09-29 |
Genpharm International Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US5258359A
(en)
|
1991-08-02 |
1993-11-02 |
Monsanto Company |
Glyphosant-containing herbicidal compositions comprising acetylenic diol rainfastness enhancing agents
|
WO1994006908A1
(fr)
|
1992-09-11 |
1994-03-31 |
The Regents Of The University Of California |
Animaux transgeniques possedant des genes de transduction lymphocytaire cibles
|
US5877396A
(en)
|
1993-04-23 |
1999-03-02 |
Sloan Kettering Institute For Cancer Research |
Mice mutant for functional Fc receptors and method of treating autoimmune diseases
|
US6111166A
(en)
|
1994-09-19 |
2000-08-29 |
Medarex, Incorporated |
Transgenic mice expressing human Fcα and β receptors
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
AU5632296A
(en)
*
|
1995-04-27 |
1996-11-18 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
WO1998024893A2
(fr)
|
1996-12-03 |
1998-06-11 |
Abgenix, Inc. |
MAMMIFERES TRANSGENIQUES POSSEDANT DES LOCI DE GENES D'IMMUNOGLOBULINE D'ORIGINE HUMAINE, DOTES DE REGIONS VH ET Vλ, ET ANTICORPS PRODUITS A PARTIR DE TELS MAMMIFERES
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
GB9823930D0
(en)
|
1998-11-03 |
1998-12-30 |
Babraham Inst |
Murine expression of human ig\ locus
|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
US6676927B1
(en)
|
1999-01-20 |
2004-01-13 |
The Rockefeller University |
Animal model and methods for its use in the selection of cytotoxic antibodies
|
FR2807767B1
(fr)
|
2000-04-12 |
2005-01-14 |
Lab Francais Du Fractionnement |
Anticorps monoclonaux anti-d
|
JP3597140B2
(ja)
*
|
2000-05-18 |
2004-12-02 |
日本たばこ産業株式会社 |
副刺激伝達分子ailimに対するヒトモノクローナル抗体及びその医薬用途
|
US7413031B2
(en)
|
2000-07-18 |
2008-08-19 |
The Charles Machine Works, Inc. |
Apparatus and method for maintaining control of a drilling machine
|
US7105348B2
(en)
|
2000-10-31 |
2006-09-12 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
US6586251B2
(en)
|
2000-10-31 |
2003-07-01 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
WO2002043658A2
(fr)
|
2000-11-06 |
2002-06-06 |
The Jackson Laboratory |
Traitement a base de fcrn pour troubles autoimmuns
|
EP2365062B1
(fr)
|
2001-02-20 |
2016-11-23 |
University Of Georgia Research Foundation, Inc. |
Production rapide d'anticorps monoclonaux
|
FR2822161B1
(fr)
|
2001-03-15 |
2003-09-19 |
Genoway |
Cellule et animal transgenique modelisant les reponses humaines allergiques mediees par les ige, et leurs utilisations
|
JP4653915B2
(ja)
|
2001-10-29 |
2011-03-16 |
独立行政法人科学技術振興機構 |
全身性エリテマトーデスモデル非ヒト動物
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
US7662925B2
(en)
|
2002-03-01 |
2010-02-16 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
US20090042291A1
(en)
|
2002-03-01 |
2009-02-12 |
Xencor, Inc. |
Optimized Fc variants
|
WO2003104459A1
(fr)
|
2002-06-07 |
2003-12-18 |
Arthron Limited |
Modele animal transgenique de fc$g(g)riia pour affection auto-immune
|
JP2004147535A
(ja)
|
2002-10-29 |
2004-05-27 |
Japan Science & Technology Agency |
ギラン・バレー症候群及び/又はフィッシャー症候群発症モデル非ヒト動物
|
WO2004060052A2
(fr)
|
2002-12-16 |
2004-07-22 |
Genentech, Inc. |
Souris transgeniques exprimant le cd20 et/ou le cd16 humain(s)
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
US8388955B2
(en)
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
FR2858235B1
(fr)
|
2003-07-31 |
2006-02-17 |
Lab Francais Du Fractionnement |
Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs
|
US8218805B2
(en)
|
2003-10-11 |
2012-07-10 |
Charles Hornback |
Wireless speaker system for use with ceiling fans
|
WO2005063815A2
(fr)
|
2003-11-12 |
2005-07-14 |
Biogen Idec Ma Inc. |
Variants de polypeptides de liaison au recepteur fc$g(g) et procede apparentes
|
KR20050047030A
(ko)
*
|
2003-11-13 |
2005-05-19 |
한미약품 주식회사 |
약물의 캐리어로서 유용한 IgG Fc 단편 및 그의제조방법
|
AU2005227313A1
(en)
*
|
2004-03-19 |
2005-10-06 |
Amgen Inc. |
Reducing the risk of human and anti-human antibodies through V gene manipulation
|
AU2005250408B2
(en)
|
2004-05-27 |
2010-09-23 |
The Trustees Of The University Of Pennsylvania |
Novel artificial antigen presenting cells and uses therefor
|
AU2005295269B2
(en)
|
2004-10-19 |
2010-05-13 |
Regeneron Pharmaceuticals, Inc. |
Method for generating an animal homozygous for a genetic modification
|
AU2005335714B2
(en)
|
2004-11-10 |
2012-07-26 |
Macrogenics, Inc. |
Engineering Fc antibody regions to confer effector function
|
US20060222653A1
(en)
|
2004-11-12 |
2006-10-05 |
Xencor, Inc. |
Antibodies operably linked to selected chemoattractants
|
EP1858925A2
(fr)
|
2005-01-12 |
2007-11-28 |
Xencor, Inc. |
Anticorps et proteines de fusion fc a immunogenicite modifiee
|
US20070190063A1
(en)
|
2005-08-19 |
2007-08-16 |
Bahjat Keith S |
Antibody-mediated enhancement of immune response
|
CA2644903A1
(fr)
|
2006-03-10 |
2007-09-20 |
Macrogenics, Inc. |
Identification et modification genetique d'anticorps avec des chaines lourdes de variants et leurs procedes d'utilisation
|
US7910798B2
(en)
|
2006-03-31 |
2011-03-22 |
Medarex, Inc. |
Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
|
US20080003225A1
(en)
|
2006-06-29 |
2008-01-03 |
Henri Vie |
Method for enhancing the antibody-dependent cellular cytotoxicity (ADCC) and uses of T cells expressing CD16 receptors
|
WO2008028068A2
(fr)
|
2006-08-30 |
2008-03-06 |
Genentech, Inc. |
POLYPEPTIDES FCεR1α DE PRIMATES NON HUMAINS
|
SG174053A1
(en)
|
2006-09-01 |
2011-09-29 |
Therapeutic Human Polyclonals Inc |
Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
|
US20090053210A1
(en)
|
2006-09-01 |
2009-02-26 |
Roland Buelow |
Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
|
US8042033B2
(en)
|
2006-11-29 |
2011-10-18 |
Lg Electronics Inc. |
Protection of access information in wireless communications
|
EP2123754B1
(fr)
|
2007-01-30 |
2011-04-06 |
Forerunner Pharma Research Co., Ltd. |
RECEPTEUR Fc GAMMA CHIMERIQUE ET PROCEDE DE DETERMINATION DE L'ACTIVITE ADCC PAR UTILISATION DU RECEPTEUR
|
US7816082B2
(en)
|
2007-03-06 |
2010-10-19 |
The Arizona Board Of Regents On Behalf Of The University Of Arizona |
Methods of identifying pancreatic cancer cells
|
PT2195023T
(pt)
*
|
2007-08-29 |
2018-06-08 |
Sanofi Sa |
Anticorpos anti-cxcr5 humanizados, seus derivados e suas utilizações
|
KR20100103810A
(ko)
|
2007-12-10 |
2010-09-28 |
알리바 바이오파마수티컬스, 아이엔씨. |
동종 재조합에 의한 표적화된 영역의 순차적인 치환 방법
|
US8658766B2
(en)
|
2008-06-27 |
2014-02-25 |
Zymogenetics, Inc. |
Soluble hybrid Fcγ receptors and related methods
|
US20110142857A1
(en)
|
2008-07-23 |
2011-06-16 |
Rappaport Family Institue For Reseach In The Madical Sciences Efron Street |
Methods of altering peripheral b cell populations and uses thereof
|
GB0909906D0
(en)
*
|
2009-06-09 |
2009-07-22 |
Affitech As |
Antibodies
|
US9445581B2
(en)
*
|
2012-03-28 |
2016-09-20 |
Kymab Limited |
Animal models and therapeutic molecules
|
US20120204278A1
(en)
|
2009-07-08 |
2012-08-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
CA2781159A1
(fr)
|
2009-11-17 |
2011-05-26 |
Kyowa Hakko Kirin Co., Ltd. |
Vecteur de chromosome artificiel humain
|
KR101553244B1
(ko)
*
|
2009-12-10 |
2015-09-15 |
리제너론 파마슈티칼스 인코포레이티드 |
중쇄 항체를 만드는 마우스
|
KR102092744B1
(ko)
|
2009-12-21 |
2020-03-24 |
리제너론 파마슈티칼스 인코포레이티드 |
인간화된 FcγR 마우스
|
US8883496B2
(en)
|
2009-12-21 |
2014-11-11 |
Regeneron Phamaceuticals, Inc. |
Humanized FcgR mice
|
US9796788B2
(en)
|
2010-02-08 |
2017-10-24 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
US20130185821A1
(en)
|
2010-02-08 |
2013-07-18 |
Regeneron Pharmaceuticals, Inc. |
Common Light Chain Mouse
|
JP2013523098A
(ja)
|
2010-03-29 |
2013-06-17 |
ザイムワークス,インコーポレイテッド |
強化又は抑制されたエフェクター機能を有する抗体
|
TWI667257B
(zh)
*
|
2010-03-30 |
2019-08-01 |
中外製藥股份有限公司 |
促進抗原消失之具有經修飾的FcRn親和力之抗體
|
NZ605966A
(en)
|
2010-06-17 |
2015-04-24 |
Kymab Ltd |
Animal models and therapeutic molecules
|
PL3034608T3
(pl)
|
2010-06-22 |
2019-08-30 |
Regeneron Pharmaceuticals, Inc. |
Myszy wykazujące ekspresję hybrydowego łańcucha lekkiego immunoglobuliny z ludzkim regionem zmiennym
|
MX2018014787A
(es)
|
2010-08-02 |
2023-02-14 |
Regeneron Pharma |
Ratones que producen proteinas de union que comprenden dominios vl.
|
PL2738258T5
(pl)
|
2011-02-25 |
2023-05-15 |
Regeneron Pharmaceuticals, Inc. |
Myszy adam6
|
JP5893258B2
(ja)
|
2011-03-31 |
2016-03-23 |
フェリカネットワークス株式会社 |
情報処理装置および方法、並びにプログラム
|
WO2013059230A1
(fr)
|
2011-10-17 |
2013-04-25 |
Regeneron Pharmaceuticals, Inc. |
Souris à chaîne lourde d'immunoglobuline limitée
|
US9591835B2
(en)
|
2011-10-28 |
2017-03-14 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified major histocompatibility complex animals
|
PT2770821T
(pt)
|
2011-10-28 |
2017-12-18 |
Regeneron Pharma |
Ratinhos de complexo principal de histocompatibilidade principal modificados geneticamente
|
SG10201909638UA
(en)
|
2011-10-28 |
2019-11-28 |
Regeneron Pharma |
Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii molecules
|
US8878001B2
(en)
|
2011-10-28 |
2014-11-04 |
Regeneron Pharmaceuticals, Inc. |
Humanized IL-6 and IL-6 receptor
|
WO2013063702A1
(fr)
|
2011-11-04 |
2013-05-10 |
Zymeworks Inc. |
Structure d'anticorps hétérodimérique stable comprenant des mutations dans le domaine fc
|
US20140013456A1
(en)
|
2012-03-16 |
2014-01-09 |
Regeneron Pharmaceuticals, Inc. |
Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
|
PL2825037T4
(pl)
|
2012-03-16 |
2020-03-31 |
Regeneron Pharmaceuticals, Inc. |
Gryzonie eksprymujące sekwencje immunoglobuliny wrażliwej na pH
|
KR102228296B1
(ko)
|
2012-03-16 |
2021-03-17 |
리제너론 파마슈티칼스 인코포레이티드 |
히스티딘 공학처리된 경쇄 항체 및 그것을 생성하기 위한 유전자 변형된 비-사람 동물
|
CA2865644A1
(fr)
|
2012-03-16 |
2013-09-19 |
Regeneron Pharmaceuticals, Inc. |
Souris produisant des proteines de liaison a l'antigene ayant des caracteristiques de liaison dependant du ph
|
JP2015512635A
(ja)
*
|
2012-03-28 |
2015-04-30 |
カイマブ・リミテッド |
クラススイッチした完全ヒト抗体の発現のためのトランスジェニック非−ヒト脊椎動物
|
GB2502127A
(en)
*
|
2012-05-17 |
2013-11-20 |
Kymab Ltd |
Multivalent antibodies and in vivo methods for their production
|
US10251377B2
(en)
|
2012-03-28 |
2019-04-09 |
Kymab Limited |
Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
|
JP5920830B2
(ja)
|
2012-09-28 |
2016-05-18 |
シスメックス株式会社 |
試料調製装置および細胞分析装置
|
EP2914102B1
(fr)
|
2012-11-05 |
2017-10-18 |
Regeneron Pharmaceuticals, Inc. |
Animaux non humains génétiquement modifiés et leurs procédés d'utilisation
|
SG11201505383UA
(en)
|
2013-02-20 |
2015-08-28 |
Regeneron Pharma |
Non-human animals with modified immunoglobulin heavy chain sequences
|
DK2958938T3
(da)
|
2013-02-20 |
2019-07-15 |
Regeneron Pharma |
Mus, der eksprimerer humaniserede T-celle-co-receptorer
|
US20150342163A1
(en)
|
2013-02-22 |
2015-12-03 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified major histocompatibility complex mice
|
PL2958937T3
(pl)
|
2013-02-22 |
2019-01-31 |
Regeneron Pharmaceuticals, Inc. |
Myszy ekspresjonujące humanizowany główny układ zgodności tkankowej
|
BR112015026197B1
(pt)
|
2013-04-16 |
2022-12-06 |
Regeneron Pharmaceuticals, Inc |
Método para modificação marcada de um lócus genômico de interesse em uma célula de rato pluripotente
|
EP2837637A1
(fr)
*
|
2013-08-16 |
2015-02-18 |
SuppreMol GmbH |
Nouveaux anticorps de type IgG anti-FcyRIIB
|
KR102370419B1
(ko)
|
2013-09-23 |
2022-03-04 |
리제너론 파마슈티칼스 인코포레이티드 |
인간화된 신호-조절 단백질 유전자를 가지는 비-인간 동물
|
AU2014353346B2
(en)
|
2013-11-19 |
2020-05-14 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals having a humanized B-cell activating factor gene
|
RU2725520C2
(ru)
|
2013-12-11 |
2020-07-02 |
Регенерон Фармасьютикалс, Инк. |
Способы и композиции для направленной модификации генома
|
JP6267986B2
(ja)
*
|
2014-02-13 |
2018-01-24 |
株式会社特殊免疫研究所 |
ヒトの特定分子と結合する分子標的物質のinvivo評価法
|
PL3129400T3
(pl)
*
|
2014-04-08 |
2020-09-07 |
Regeneron Pharmaceuticals, Inc. |
Zwierzęta inne niż człowiek mające humanizowane receptory fc-gamma
|
NO2785538T3
(fr)
|
2014-05-07 |
2018-08-04 |
|
|
CA2947309A1
(fr)
|
2014-05-19 |
2015-11-26 |
Regeneron Pharmaceuticals, Inc. |
Animaux non humains genetiquement modifies exprimant l'epo humaine
|
CN106795521B
(zh)
|
2014-06-06 |
2021-06-04 |
瑞泽恩制药公司 |
用于修饰所靶向基因座的方法和组合物
|
ES2783424T3
(es)
|
2014-06-19 |
2020-09-17 |
Regeneron Pharma |
Animales no humanos que tienen un gen de muerte celular programada 1 humanizado
|
DK3155099T3
(en)
|
2014-06-23 |
2018-05-07 |
Regeneron Pharma |
NUCLEASE MEDIATED DNA COLLECTION
|
KR20240055876A
(ko)
|
2014-11-24 |
2024-04-29 |
리제너론 파마슈티칼스 인코포레이티드 |
인간화 cd3 복합체를 발현하는 비인간 동물
|
EP3850946B1
(fr)
|
2014-12-05 |
2023-09-27 |
Regeneron Pharmaceuticals, Inc. |
Animaux non humains ayant un groupe humanisé de gène de différenciation 47
|
HUE052606T2
(hu)
|
2014-12-09 |
2021-05-28 |
Regeneron Pharma |
Humanizált differenciációs klaszter 274 génnel rendelkezõ nem humán állatok
|
PT3280257T
(pt)
|
2015-04-06 |
2023-09-12 |
Regeneron Pharma |
Respostas imunes mediadas por células t humanizadas em animais não humanos
|
CN107529739B
(zh)
*
|
2015-04-30 |
2021-01-08 |
株式会社特殊免疫研究所 |
表达人特定分子和人Fcγ受体家族的转基因非人动物
|
EP3297430A4
(fr)
*
|
2015-05-22 |
2019-01-23 |
Champions Oncology, Inc. |
Souris humanisées et leurs utilisations
|
WO2016203597A1
(fr)
*
|
2015-06-18 |
2016-12-22 |
株式会社トランスジェニック |
Souris humanisée par un organe
|
JP6837436B2
(ja)
*
|
2015-07-10 |
2021-03-03 |
中外製薬株式会社 |
内因性cd3遺伝子をヒトcd3遺伝子に置換した非ヒト動物
|
WO2017087780A1
(fr)
|
2015-11-20 |
2017-05-26 |
Regeneron Pharmaceuticals, Inc. |
Animaux non humains ayant un gène d'activation des lymphocytes 3 humanisé
|
KR20240016444A
(ko)
|
2016-05-20 |
2024-02-06 |
리제너론 파마슈티칼스 인코포레이티드 |
다중 가이드 RNAs를 이용한 면역학적 내성 파괴 방법
|
RS60886B1
(sr)
|
2016-11-04 |
2020-11-30 |
Regeneron Pharma |
Ne-humane životinje koje imaju konstruisani lokus imunoglobulinskog lamba lakog lanca
|
WO2019006034A1
(fr)
|
2017-06-27 |
2019-01-03 |
Regeneron Pharmaceuticals, Inc. |
Animaux non humains comprenant un locus asgr1 humanisé
|
EP3585164B1
(fr)
|
2017-11-30 |
2023-12-27 |
Regeneron Pharmaceuticals, Inc. |
Rats comprenant un locus trkb humanisé
|
SG11202008620VA
(en)
|
2018-03-26 |
2020-10-29 |
Regeneron Pharma |
Humanized rodents for testing therapeutic agents
|